Introduction
T he debate on the implications of liberalising import r estrictions and production controls on pharmaceutical products in India was rekindled with the decision to i mplement product patent rights. The removal of regulations that insisted on local production, placing pharmaceuticals in the open general licence (OGL) category and the abolition of rest rictions on foreign fi rms were all expected to e ncourage imports of pharmaceutical products into India. With the new patent regime, it was apprehended that growth in exports would be limited due to restrictions on the scope of operations of g eneric producers, particularly their ability to export to preferred destinations, while imports would get a boost because of the constraints on domestic producers of patented medicines, thus causing the balance of trade to deteriorate. This paper provides an analysis of the trends and patterns in pharmaceutical exports and imports in the new policy era.
The Context
The liberalisation measures in the Industrial Licensing Policy Statement of July 1991 were implemented in the pharmaceutical sector in 1994 through the Modifi cation in Drug Policy 1986. Key elements of the liberalisation measures were as follows: (a) Abolition of industrial licensing for all bulk drugs and their intermediaries and for all formulations except specifi c cell/ tissue-targeted ones; (b) Elimination of the ratio parameter linking the production of formulations to that of indigenous production of bulk drugs from the basic stages; (c) Abolition of restrictions on import of drugs and pharmaceuticals and placing them in the OGL category; (d) Reduction in tariffs for the import of pharmaceuticals; (e) Automatic approval of foreign direct investment (FDI) up to 100%; and (f) Relaxation of the drug price control mechanism.
These measures essentially came about as a result of the e ndogenous policymaking process, but the most signifi cant policy change in the post-1994 period -the change in the patent regime -came about as an outcome of India's obligations under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. The concern that liberalisation would r esult in an increased dependence on imports was aggravated by the decision to implement product patent rights in the p harmaceutical sector. Studies have established a positive corre lation between the strengthening of patent rights in d eveloping countries and increased exports to these countries by companies based in developed countries. It was feared that the I ndian pharmaceutical industry would no longer be able to e xport generics of on-patent drugs, which had been a thriving business in the past. Maskus and Penubarti (1995) and Smith (1999) found a strong positive correlation between exports and the level of intellectual property protection in importing countries. Smith (1999) observed that strengthening patent rights in countries that pose a strong threat of imitation would expand exports, whereas strong patent rights in countries where the threat of imitation is weak would enhance market power. India was classifi ed as a country with weak patent rights and strong imitative abilities where a strengthening of patent rights would bring about market expansion. Following this reasoning, it was expected that imports to India would expand with the implementation of product patent rights and this would adversely affect the balance of trade. The other view, however, was that the rise in imports of formulations would be offset by the growth in exports of bulk drugs (Lanjouw 1999) . Further, the expiry of blockbuster patents was expected to provide Indian fi rms with new opportunities for exports. It was also expected that the cost advantages of production in India, compliance with good manufacturing practices and the expertise in r everse engineering would make Indian fi rms explore new o pportunities in low-volume, high-price regulated markets while retaining their traditional low-price, high-volume markets in Asia, Africa and Latin America (Grace 2004) . Chaudhuri (2005) showed that there has been a remarkable growth in Indian pharmaceutical exports, particularly after 2000. The growth in exports to regulated markets, especially the US, has been the major reason for the spurt. Exports to regulated markets accounted for 39% of the exports in 2001-02. Dhar and Gopakumar (2008) arrived at a similar conclusion. Chaudhuri also pointed out that in 2001-02, formulations c onstituted 52% of the exports with the remaining being bulk drugs. 1 However, there are no major studies providing detailed analyses of imports of pharmaceuticals to India. This study a ttempts to fi ll the gap and also endeavours to capture the more recent trends in exports.
Methodology
The analysis is based on data accessed from COMTRADE. 2 The advantage of this data is that it enables cross-country comparisons as it is based on an international classifi cation, the Standard International Trade Classifi cation (SITC). Major inter national statistical publications, including the annual Inter national Trade Statistics brought out by the World Trade O rganisation (WTO), follow the SITC and use COMTRADE data to identify m ajor exporters and importers. As countries need not strictly follow the SITC for domestic purposes, there may be differences in the fi gures reported by COMTRADE and g overnment sources. For example, while COMTRADE and International Trade Statistics report that India's exports in pharmaceuticals in 2008 was $5.9 billion, the annual report of the union government's d epartment of pharmaceuticals reports a fi gure of $8.4 billion for 2008-09. 3 Pharmaceutical products are classifi ed into formulations (dosage forms) and bulk drugs (active pharmaceutical ingredients, or APIs). The European Medicines Agency (EMA) defi nes a formulation as "the physical manifestation that contains the active and/or inactive ingredients that deliver a dose of the medicinal product. The key defi ning characteristics of the dose form can be the state of matter, delivery method, release characteristics and the administration site or route for which the product is formulated. A pharmaceutical dose form is the form in which a pharmaceutical product is presented in the medicinal product package as supplied by the marketing authorisation holder/manufacturer/distributor". 4 The US Food and Drug Administration (FDA) defi nes a bulk drug as "any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) and that when used in its production becomes an active ingredient of the drug product. Such substances are intended to furnish pharma cological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body." 5 In India, these terms are defi ned in the Drugs Price Control Order (DPCO). The DPCO defi nes a formulation as "a medicine processed out of, or containing the use of any one or more bulk drug or drugs with or without pharmaceutical aids, for internal or external use for or in the diagnosis, treatment, mitigation or prevention of disease" 6 and a bulk drug as "any pharmaceutical, chemical, biological or plant product including its salts, esters, stereo-isomers and derivatives, conforming to pharmacopoeial or other standards specifi ed in the Second Schedule to the Drugs and Cosmetics Act, 1940 Act, (23 of 1940 , and which is used as such or as an ingredient in any formulation."
The SITC does not explicitly use these terms (formulation and bulk drug), but classifi es pharmaceutical products into two groups -code 541 "medicinal and pharmaceutical products, other than medicaments of group 542" representing bulk drugs and code 542 "medicaments (including veterinary medicaments)" representing formulations. Code 541 consists of s elected products from harmonised system (HS) chapters 26, 29 and 30. Code 542 consists of selected products from HS chapter 30 (3003 and 3004). HS chapter 30, which is on pharmaceutical products, has six sub-chapters (at four digits) and the term "'medicaments" apply only to sub-chapters 3003 7 and 3004, 8 indicating these two are d istinct from the other four sub-chapters. For this study, products coming under SITC code 541 (which in the HS classifi cation are select products from chapters 26, 29 and the products under chapters 3001, 3002, 3005 and 3006) are considered bulk drugs and products coming under SITC code 542 (which in the HS classi fi cation are products under chapters 3003 and 3004) are c onsidered formulations. My interaction with offi cials of the Bulk Drug Manufacturers' Association ( India), Hyderabad confi rmed that HS 3003 and 3004 are considered as formulations by the pharmaceutical i ndustry. Table 1 gives a detailed HS classifi cation of bulk drugs and f ormulations (at six-digit level). The study also uses, wherever relevant, data from the I ndian Drug Manufacturers' Association (IDMA) and the Prowess d atabase of the Centre for Monitoring Indian Economy (CMIE).
Trends in Pharmaceuticals Trade
India ranks fi fth in the world on the list of leading exporters of pharmaceuticals in the International Trade Statistics report. The 2009 report shows that India accounted for 1.4% of global exports. This is remarkable given that India's ranking was sixth and its share in global pharmaceutical exports was 1% in the 2005 report. In the domestic export basket as well, the share of the pharmaceutical sector has been increasing -from 2.8% in 2005 to 3.3% in 2009. 10 India does not have signifi cant imports of pharmaceuticals and the country does not fi gure in the list of leading importers in the WTO report. T able 2 shows trends in the export and import of pharmaceutical products since 1994.
The Indian pharmaceutical sector shows a steadily growing positive trade balance. The surplus has been contributed by formulations, which accounted for 78% of the exports in 2009. However, in bulk drugs, the country has had a negative trade balance in many years.
Most of the leading exporters of pharmaceuticals are d omestic fi rms and they derive a substantial share of sales from exports (Table 3) .
Ranbaxy and Matrix were fl agship Indian pharmaceutical companies until they were taken over by multinational corporations (MNCs) a few years ago. 11 There are a few more such fi rms that have substantial exports in their sales turnover. 12 For this analysis, the taken-over companies are treated as a separate category. Figure 1 gives the export intensity, defi ned as the exports to sales ratio of MNCs, domestic fi rms and the taken-over fi rms. The taken-over fi rms are the most export-o riented and
MNCs are the least export-oriented. While the taken-over fi rms had an exports-sales ratio of 71% in 2008-09, it was only 11% for MNCs. That the MNCs operating in India do not have signifi cant exports is contrary to the general understanding that foreign fi rms will be more export-oriented. Firms investing abroad are expected to show greater export competitiveness as their presence in foreign market ensures fl exibility, reliability and timeliness in dealing with global buyers, which is crucial for export success (Kumar and Jayaprakash 2007) . This expectation was explicitly mentioned in the Industrial Policy Statement of 1991, which initiated liberalisation of FDI rules in the pharmaceutical sector. The statement read, "Foreign investment would bring attendant advantages of techno logy transfer, marketing expertise, introduction of modern managerial techniques and MNCs to get into the generic business as well. 13 They have opted for taking over leading players in the generic segment instead of doing it the organic way. This is precisely why the taken-over fi rms in India are the most export-oriented. Daiichi took over Ranbaxy when the government of Japan d ecided to take measures that would help increase the share of generic drugs from 17% to 30% by 2012. Daiichi now has its nose in front in the expanding generic market because it is getting Ranbaxy's cheap, high-quality manufacturing facilities (Joseph 2008) . MNCs taking over generic fi rms have not been limited to India. They have taken over domestic drug companies in other countries as well, such as Sanofi Aventis taking over Medley in Brazil and Zantiva in the Czech Republic and GSK taking over BMS in Egypt and Pakistan. 14 A survey of 50 top industry executives quoted in the Financial Times reported that 65% of the executives considered that their sector was facing a "strategic crisis" and 67% saw diversifi cation as a p otential solution. 15 Sanofi Aventis has been the leading company in diversifi cation over the last few years, boosting nonpatented drug sales from 5% to 12% between 2004 and 2009.
In imports of pharmaceutical goods (excluding raw materials), the leading players are foreign fi rms (Table 3) . When fi rms in the Prowess database are categorised on the basis of their ownership, it is found that foreign fi rms have an importssales ratio of 40% whereas the ratio for domestic fi rms is only 5% (in 2009). The taken-over fi rms do not have any imports. There was a jump in the imports-sales ratio of MNCs in 1995-96 (from 13% in 1994-95 to 24% in the next year) after the restrictions on imports were eliminated. In 1994, the Modifi cation to the Drug Policy 1986 removed all the restrictions on the use of imported bulk drugs. Over the years, the import duty also came down drastically. 16 Major changes have taken place in the destinations of exports and the sources of imports. In 1991, the Soviet Union was the single largest export destination. However, with the disintegration of the Soviet Union and the growing competence of Indian fi rms, the focus gradually shifted to the highly rewarding (lowvolume, high-margin) regulated markets, especially the US (Table 4 ). In imports, India used to source the bulk of its r equirements from the US, Italy and Germany, but, over the years, China has r eplaced these countries as the major supplier.
Exports of Bulk Drugs and Formulations
India's pharmaceutical industry has increasingly become e xport-oriented and the share of exports in sales has steadily grown from 15% in 1993-94 to 41% in 2009-10. 17 The rates of growth of exports of both bulk drugs and formulations suggest that the industry is doing better in the post-TRIPS period (after 2005) . Figure 2 gives the annual rate of growth of bulk drugs and formulations during different time periods.
Two major changes in trends are seen in Figure 2 . One, the rate of growth of exports of bulk drugs was higher than that of formulations during the 1990s, but the opposite is true in the current decade. Two, bulk drugs which showed a steady decline in the growth of exports between 2001 and 2005, reversed the trend in the post-2005 period. Formulations, on the other hand, exhibited a steady growth in exports throughout. On the whole, it may be concluded that exports of bulk drugs and formulations have been growing at higher rates in the post-2005 period than in the 10 years of the post-1994 period.
An important factor contributing to the growth in exports of bulk drugs in the last few years has been the outsourcing of API production by MNCs. Foreign companies are keen to outsource their production for containing costs. India has become a favourable destination as it has the largest number of FDA-approved plants outside the US. In 2005, India had 60 FDA-approved plants whereas its competitor China had only 22 (PricewaterhouseCoopers 2005). We do not have information on how many of the outsourced APIs are under patent protection to warrant reaching conclusions on the impact of new intellectual property rules on outsourcing.
However, the composition of exports shows that formulations account for more than four-fi fths of pharmaceutical e xports. While bulk drugs have shown an increase in rate of growth of exports in the post-2005 period, their share in exports has consistently declined since 2000 (30% in 2000 to 17% 2008) . This raises the question whether the acceleration in the growth of exports of bulk drugs in the recent past has had any signifi cance for the pharmaceutical industry. The US has become the most desired export destination for both bulk drugs and formulations. However, formulations a ccount for the lion's share of exports to the US -87% in 2009. To market a generic drug in the US, a company needs to fi le an abbreviated new drug application (ANDA). When fi ling an ANDA, the company has to certify that its product is not infringing any patent rights or that a patent is invalid (para IV certifi cation). If it successfully proves that a patent is invalid or if it is the fi rst to get approval for the generic version, it gets market exclusivity for 180 days during which no other generic company is permitted to enter the market. This exclusivity is available under the Hatch-Waxman Act. A successful fi rst ANDA can bring immense profi ts to a company. For example, Dr Reddy's, the fi rst Indian company to market fl uoxetine 40 mg in August 2001 under 180-day exclusivity saw its sale of generics i ncrease from Rs 304 million in 2000-01 to Rs 4,066 million in 2001-02. Sale of fl uoxetine was 81% of its total generic sales and about half of its operating profi t in 2001-02 (Chaudhuri 2007) . R anbaxy was the fi rst to obtain 180 days exclusivity for this drug, but could not launch the product on time as the patent holder managed to obtain an injunction against it. 18 Patent litigation under para IV is highly risky as failure would mean a loss of several years of hard work and huge legal expenses.
Encouraged by the success of Dr Reddy's, a number of fi rms have taken steps to register themselves as fi rst movers in generics, often gaining a huge market share. Ranbaxy, in November 2009, introduced the generic version of GlaxoSmithKline's skin medicine Valtrex under 180-day market exclusivity, which enabled the company to secure 74% of the $1,400 million market before the expiry of exclusivity. 19 The launch of generic Aricept (an Alzheimer's drug, patent held by Eisai Co) after its patent expired on 25 November 2010 is expected to earn Ranbaxy about $200 million. 20 Similarly, Atorvastatin, the generic version of Lipitor, the single largest selling prescription drug in the world, is expected to fetch Ranbaxy more than $2 billion in the coming fi ve years. 21 Companies also work on developing a non-infringing process for ANDA fi ling. Matrix Laboratories was the fi rst Indian company to develop a non-infringing process for manufacturing citalopram. The company was able to reap huge benefi ts with its sales of the product amounting to Rs 5,600 million till 2005-06. Another commercially successful example is the c efotaxime process developed by Lupin (Chaudhuri 2007) .
ANDAs and drug master fi les (DMFs) data from the FDA give indications of the extent to which Indian fi rms are seeking o pportunities in the US market. The leading 10 fi rms in India got 537 ANDA approvals in the last decade, of which one-fourth carried 180-day market exclusivity. Details of ANDAs and DMFs 1991 1992 1993 1994 1995 1996 1997 1998 Table 8 (p 68).
The bulk of these activities were carried out by three fi rms, Aurobindo, Ranbaxy and Dr Reddy's. Ranbaxy and Dr Reddy's stand out for their aggressive approach to challenging patents and obtaining market exclusivity. A large percentage of Ranbaxy's (57%) and Dr Reddy's (37%) ANDA approvals had market exclusivity against the average of 23% for all the leading fi rms. Para IV fi lings involving patent litigations are a high-risk, high-return strategy. A failure could r esult in huge losses and legal expenses. The leading fi rms also have a large number of DMF fi lings, an indication of their interest in the US market. These 10 fi rms account for nearly half of all DMF fi lings made by all pharmaceutical fi rms from India. 23 An analysis of revealed comparative advantage (RCA) suggests that India's advantage lies in formulations (Figure 3) . The RCA is an index of the export performance of a country with respect to a particular commodity which captures the comparative advantage of that commodity. The RCA of a particular commodity is measured by the share of that industry in the country's total exports relative to the country's share in total world exports. The RCA index may take values from zero to infi nity, with values greater than unity indicating the existence of an RCA.
The RCA index for i th product for j th country in year t is defi ned as, RCA ij (t) = [(X ij W (t) /X io W (t) )/(X oj W (t) /X oo W (t) )] X ij w (t) = Export of i th product by the j th country to the world in the year t. X io w (t) = Total export of the i th product by all countries in the world in the year t. X oj w (t) = Total export of the country j to the world in the year t. X oo w (t) = Total export of all products by all countries in the world in the year t. Figure 3 gives two indications of the changing dynamics of the Indian pharmaceutical industry. One, the RCA index for bulk drugs shows an upward movement until 2000 and a d ecline since 2001. Since 2004, the value of the RCA index for bulk drugs is below unity, indicating a lack of comparative advantage. We saw that the share of bulk drugs in pharmaceutical exports began to decline after 2000. Two, the RCA index for formulations shows a decline until 2005 and a gradual acceleration from 2006. And the index never fell below one. 24 It is really startling that the comparative advantage indicator for formulations showed an upward movement in the post-2005 period. This is contrary to what had been anticipated by many. In global rankings of RCA for formulations, India ranks second after Switzerland among the top fi ve pharmaceutical exporting countries. India's ranking has consistently been second to Switzerland since 1994. The RCA index for formulations showed a sudden decline in 2009. This may have been because of a decline in the export of formulations in 2009 primarily because of the seizure of Indian generics in European ports while in transit for alleged infringement of patent rights. 25 The seizures have added to the cost of exporters as they have had to look for alternative trade routes to avoid European ports.
The change in export dynamics has had a direct bearing on the production dynamics of the pharmaceutical industry. Figure 4 shows that there has been a decline in the growth of bulk drugs production in the post-2005 period -it declined from around 15% during the pre-2005 period to 9% in the post-2005 period. The formulations segment shows an acceleration in production during the post-2005 period compared to the previous periods. An expansion in exports of bulk drugs and a decline in production indicate more imports. Firms are increasingly importing bulk drugs, their intermediates and fi ne chemicals against relying on indigenous production as they used to do. Data on the import of raw materials from the Prowess database shows that the share of raw materials imported in sales turnover grew from 9% in 1990-91 to 11% in 2000-01 and 14% in 2008-09. There are different levels of value addition in bulk drugs m anufacturing and the Indian bulk drugs industry seems to focus on the higher end of the value chain. The abolition of the ratio parameter linking the production of formulations to indigenously produced bulk drugs from basic stages and reductions in import duty have eased constraints on imports of bulk drugs and other raw materials. The import duty on organic chemicals, including bulk drugs, was reduced from 120% in 1990-91 to 7.5% in 2007-08. 26 Another important factor contributing to the decline in domestic production has been the implementation of Schedule M (good manufacturing practices) of the Drugs and Cosmetics Act since July 2005. As a consequence, a number of small and medium enterprises (SMEs) manufacturing bulk drugs have had to shut down operations. The SME sector has been a major producer of bulk drugs in India. The bulk drugs segment is highly competitive with a large number of players, making returns very low. The Hathi Committee (1975) had worked out the capital investedturnover ratio for bulk drugs and formulations manufacturing. It estimated 1:1 for bulk drugs at its best and 1:2.6 for formulations on an average, which in some cases would be as high as 1:7.2. Due to this, with the ratio parameter no more in force, fi rms in India tend to concentrate on the production and export of formulations while engaging in imports to source cheap raw materials.
It appears that bulk drugs are no more a major area of f ocus of the Indian pharmaceutical industry and it has adopted a different strategy in the bulk drugs segment in the post-TRIPS era. Bulk drugs as an export category do not e njoy a comparative advantage anymore though the rate of growth of exports has accelerated in recent years. Production for companies in foreign countries has been an important factor that has maintained the pace of exports. The growth in i ndigenous production of bulk drugs has declined in the post-2005 period and the industry is increasingly meeting its r equirements of bulk drugs, intermediates and other raw m aterials through imports.
The destinations of exports of formulations (regionwise) have changed in a major way in the last two decades ( Table 9 ). The share of Europe drastically declined from about two-thirds in 1991 to a quarter in 2009. On the other hand, Africa and America are increasingly becoming major export destinations. More than 80% of the exports to America are destined for North America, especially the US. Tables 9 and 10 show that exports to Asia and its subregions have fallen in this d ecade. Exports to IBSA partners (Brazil and South Africa) have shown a growing trend. Overall, the drivers of pharmaceutical exports have been North America, Africa and the IBSA partners. South America and Asia, including the subregions and regional arrangements within Asia, seem to be relatively less signifi cant to pharmaceutical exports.
The renewed vigour worldwide to enforce intellectual property rights will have implications for the Indian pharmaceutical industry given that Africa is a major export focus. Recent anti-counterfeit initiatives at various levels -the World Health Organisation (WHO), the Anti-Counterfeiting Trade Agreement (ACTA) and some free trade agreements (FTAs) with the European Union (EU) -attempt to eliminate the distinction b etween substandard (quality issue), counterfeit (trademark issue) and generic (patent issue) drugs. In the process, legitimate generics (for which no patent exists in the exporting country or importing country) have been targeted under the counterfeit label. Such initiatives, supported by pharmaceutical lobbies and the EU, have found takers in developing countries, especially in east Africa. The east African region has recently seen a few policies and legislations coming up to address the counterfeit drug problem. Kenya adopted the Kenya AntiCounterfeit Act in 2008 27 and Tanzania and Uganda propose to enact similar laws. The culmination of all these initiatives has been a regional anti-counterfeit policy and law -the East African Community Policy on Anti-Counterfeiting, AntiPiracy and Other Intellectual Property Rights Violations 28 and the East African Community Anti-Counterfeit Bill, 2010 (Musungu 2010) .
The Kenyan law raised considerable public debate on how such laws might affect access to generic drugs. It states that copies or generic versions of all products having patent protection in Kenya or elsewhere can be considered "counterfeit" in case of an intellectual property dispute with the patent holder. This may classify a genuine drug exported from India to Kenya as a counterfeit drug if a company that does not hold a patent for that particular drug either in India or Kenya but in some third country raises a dispute over it. The Kenyan law, however, was challenged in the country's high court 29 by three people living with HIV/AIDS on the grounds that it would adversely affect their access to affordable generic HIV drugs. The petitioners held that the Act confused quality and intellectual property rights issues, thereby defi ning legitimate generic drugs as counterfeits. Satisfi ed with the petition, Justice Mwendoh issued interlocutory orders on 23 April 2010 suspending the powers of the anti-counterfeit agency to interfere with the import and distribution of generic medicines in Kenya. 30 Indian pharmaceutical exporters have expressed concern that legislations like that of Kenya could seriously a ffect the country's exports. 31 
Imports of Bulk Drugs and Formulations
The import substitution policy adopted by the pharmaceutical sector successfully eliminated a heavy dependence on imports. Currently, the dependence is around 11% of the production (Table 11 ). However, in the bulk drugs segment, the industry still has a high dependence on imports, which account for 40% of the production. 32 The high import-production ratio is because of the increase in the value of imports as well as the decline in the growth of domestic production. In contrast, in formulations, imports account for only 5% of the production. Unlike in the case of exports where formulations had a major share (78% in 2009), bulk drugs account for the lion's share in imports, often exceeding two-thirds of the total ( Table 2 ).
The increasing dependence on imports of bulk drugs, which prima facie seems to be undesirable, needs to be seen in the context of the changing dynamics of the industry. Import d ependence of the pharmaceutical industry fi ve decades ago was because of the lack of manufacturing capabilities. The situation has changed and the increasing dependence of the present time is not due to lack of capabilities, but due to the availability of cheaper intermediates and bulk drugs in foreign countries. The increasing export-orientation of the industry has forced fi rms to look for cheaper inputs to maintain their competitive advantage in the international market. The increasing dependence on bulk drugs, intermediates and other raw materials is an outcome of the shift in the orientation of the export composition of the industry -it is becoming more and more formulations-oriented, and that too with the brand India image (good quality at a low price). 33 When fi rms are oriented towards the domestic market, there are few incentives to reduce the cost of production because about 50% of the drugs in the retail market in India are under a cost-based price control system (100% of the drugs were under price control in 1970, which came down to 90% in 1979, 70% in 1987 and 50% in 1995) that assures companies a predefi ned rate of return. The incentives go to promoting products rather than innovating to reduce cost, which explains why high amounts are spent on advertising and marketing instead of research and development (R&D) by both MNCs and Indian fi rms. The Indian pharmaceutical industry spent 4.8% of its sales turnover on R&D in 2008-09 whereas its spending on advertisements and marketing was 6%. 34 As fi rms increasingly enter foreign markets, cost becomes a critical factor and they import cheaper raw materials to curtail the cost of production. As the industry gradually sheds its focus on bulk drugs in its external orientation, there is little to gain from the brand India image in the case of formulations and therefore no compulsions for production within India.
The view that the increasing emphasis being placed on the export of formulations is resulting in increased imports of bulk drugs, intermediates and other raw materials is further strengthened by the observation that there is a positive association between exports and imports of raw materials. The r atio of exports to imports of raw materials shows that the taken-over fi rms, the most export-oriented fi rms, have the highest ratio ( Figure 5 ). And the MNCs, which are the least e xport-oriented, have the lowest ratio. Leading producers of bulk drugs have recently entered the formulations business in partnership with foreign fi rms. A urobindo Pharma, a major producer of bulk drugs, entered into agreements with AstraZenica in 2010 and Pfi zer in 2009 for the supply of a number of formulations, which are expected to fetch it $350-$500 million in the coming years. 35 To meet the demand, the company is increasingly engaged in the import of raw materials. The share of imports of raw materials in the company's sales turnover increased from 31% in 2000-01 to 42% in 2008-09. Table 12 lists the leading importers of raw materials in the pharmaceuticals sector in India. Most of the top exporters of pharmaceuticals (fi nished goods; Table 3 ) fi gure in the list of top 10 importers of raw materials.
Though we do not have precise data to back this view, the available indications suggest that the industry is focusing on the higher end of the value chain in the production of bulk drugs. There are no data available separately on the production of fi nal bulk drugs and their intermediates. But the i ncrease in imports of pharmaceutical raw materials and the fast growth of exports of APIs in recent years, especially to the US, indicate that imported raw materials and intermediates are processed in FDA-approved plants into fi nal APIs and then exported to clients in the US and other countries. This strategy makes economic sense, but it may place the industry in trouble if an adequate supply of raw materials cannot be guaranteed in the long term. The threat becomes more serious when imports are sourced from a single country -an interruption in the supply from a single country can put the whole industry in jeopardy. India's dependence on imports (for bulk drugs and other raw materials) is increasingly shifting to a single country -China. In 2009, imports from China accounted for 52% ($686 million) of the total imports of bulk drugs ( Figure 6 ). The report of the task force on the strategy for enhancing exports of pharmaceutical products 36 has pointed out that the Indian pharmaceutical sector has been sourcing its requirement of chemical intermediates and bulk drugs in large quantities from China for some time; at times almost 60% to 70% of our requirement of intermediates. A recent crackdown on the chemical industry in China to enforce environmental legislation resulted in a shortage of supply and a hike in prices, affecting not only the bottom lines of Indian companies but also the very existence of many fi rms. Due to shortage of raw materials and their rising prices, about 50 bulk drug manufacturing units have been shut down while others have cut down manufacturing of loss-making drug categories. 37 India's dependence on China is such that it does not have adequate domestic m anufacturing capacity to meet the demand for intermediates and bulk drugs if supplies from the neighbour cease for u nforeseen reasons.
Cost advantage is the factor driving Indian manufacturers to shun indigenous production and engage in imports. For example, theophiline from China is 10% cheaper compared to the cost of indigenous production. Chinese fi rms are able to sell bulk drugs at lower prices not only due to subsidies (for example, power subsidies), but also due to better techno logies. For example, in fermentation (an essential process in the production of bulk drugs), Indian fi rms still use sugar whereas the technology in China enables its fi rms to use caulifl ower, which is much cheaper. 38 To revive the domestic production of bulk drugs, concerted efforts need to be undertaken on various fronts. A task force of the Department of Commerce (2008) on the strategy for increasing exports of pharmaceutical products suggested that India create a policy environment that enables its small and medium chemical industry to position itself to address the back-end needs of the pharmaceutical industry. Reviving the production of bulk drugs also needs new environment-friendly technologies. Basic drugs and pharmaceuticals are among the 17 high-polluting industries identifi ed by the Central Pollution Control Board. Techno logies such as biocatalysts reduce the number of chemical processes and hence the amount of pollution. Although this technology is in use in food production and environmental management in developed countries, it hardly exists in drug production. Since the developed countries have systematically outsourced bulk drug production to developing countries such as India and China, we need not expect they are going to pass on such technologies as well (Department of Commerce 2008).
In formulations, however, the country did not face any spurt in imports with the change in the patent law. Imports of f ormulations continue to account for 5% of its production and this ratio was the same even before the TRIPS provisions were fully implemented. MNCs have been the major importers and S witzerland is the major source of supply, accounting for 39% in 2009. Though it may take some more time to know how exactly the new intellectual property rights regime is going to affect imports of formulations, our patent law has suffi cient safeguards to prevent frivolous patents and evergreening, which has been a major reason for the restricted operability of generic fi rms in countries such as the US. To the extent that India is able to prevent frivolous patents and Indian fi rms are able to produce generics, the threat of increased imports of formulations is diluted. Importing generic formulations will not be a viable strategy for MNCs to compete with producers of generics in India. The FDA approved 305 new medical entities (NMEs) between 1995 and 2004. Of these, patents for 298 had expired before 1995 and Indian fi rms will be able to produce them. Of the remaining seven NMEs, Indian fi rms had obtained marketing approval in India for three before 2005. 39 The I ndian Patents Act provides that those drugs for which signifi cant investment has gone into production and marketing will continue to be produced and marketed with payment of royalties in case they (application in the mail-box) get patents after 2005. In 2010, there were only four NMEs that were candidates for patent protection in India. If India continues to apply a high threshold for patents, there will not be too many patented drugs for which domestic production cannot provide generic substitutes. If generic substitutes are available, it is less likely that MNCs will import the drugs from their parent fi rms. Therefore, the threat of a spurt in imports of formulations may not be a real in the near future.
Conclusions
The export orientation of the Indian pharmaceutical industry has undergone a change with the amendment in the intellectual property rights regime. There are two aspects to this. First, it has become more export-oriented in order to counter the threat of reduced domestic operability and to remain in business. Second, of the two export categories -bulk drugs and formulations -the focus has shifted to formulations. The acceleration in the export of formulations has mostly been driven by the US, Africa and IBSA partners and the growth in exports to neighbouring countries and to Latin America remains at a relatively lower level. Africa being a major destination of exports, an overzealous drive to enforce intellectual property rights under the guise of an anti-counterfeit initiative in the region, especially in east Africa, is a cause of concern for the Indian pharmaceutical industry.
The change in the export orientation has resulted in a change in the production structure. To maintain their price competitiveness in the international market, Indian fi rms have had to look at options for reducing cost, a compulsion they did not face when they were mainly focused on the domestic market. The drug price control system that covered a substantial part of the retail medicine market assured them a predefi ned rate of profi ts. Hence the incentive was not directed towards reducing costs but promoting products. As a result, imports from cheaper sources of bulk drugs, their intermediates and other raw materials began to increase, while domestic production from basic stages began to decline. More than 50% of bulk drugs and other raw materials are now imported from China. A heavy dependence on a single country for raw materials puts the industry at risk. As imports of bulk drugs and other raw materials continue to grow, the industry continues to have a negative trade balance in the bulk drugs category. However, in formulations, the industry has a substantial surplus, which offsets the defi cit of the bulk drugs segment. Overall the industry thus has a trade surplus. In formulations, imports have not surged because adequate safeguards have been built into the Patents Act. These protections limit the number of patented drugs in the country and also provide space for generic competition. Imports of formulations, though very limited, are done mostly by the MNCs. Gopakumar (2010) .
